Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Duolingo Inc (DUOL) Price & Performance

Charles River Laboratories Intl. IncTrade
Duolingo IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Duolingo Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Duolingo Inc trades at $134.23 (market cap $6.34B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.1× Duolingo Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

CRLDUOL
Market Cap
$13.46B$6.34B
Sector
HealthTechnology
52-Week High
$282.00$369.19
52-Week Low
$145.57$90.03
Enterprise Value
$16.30B$5.11B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Duolingo Inc

Duolingo (DUOL) trades at $134.63, down 1.87% amid mixed signals. The stock shows strong fundamentals with impressive revenue growth from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $134 and resistance at $138. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with robust user growth and profitability metrics, but near-term pressure exists from decelerating booking growth and margin concerns. Analyst consensus is mixed with 30% buy ratings and a $121 price target below current levels. Key risks include monetization challenges despite user growth and increased competitive pressures in the education technology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL